SCHEDULE 13G/A: Brii Biosciences Discloses 3.1% Passive Stake in AN2 Therapeutics
Beneficial Ownership Report
Brii Biosciences Limited has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.1% in AN2 Therapeutics, Inc. as of December 31, 2024.
Summary
- Brii Biosciences Limited, a Cayman Islands entity, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in AN2 Therapeutics, Inc.
- As of December 31, 2024, Brii Biosciences Limited beneficially owns 927,201 shares of AN2 Therapeutics, Inc. common stock.
- This ownership represents 3.1% of AN2 Therapeutics, Inc.'s common stock outstanding.
- The percentage is calculated based on 29,878,890 shares of common stock outstanding as of November 6, 2024, as reported in AN2 Therapeutics' Form 10-Q for the quarter ended September 30, 2024.
- Brii Biosciences Limited holds sole voting power and sole dispositive power over all 927,201 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would significantly alter the sentiment towards the company's operational or financial performance.
Positives
- The filing indicates a continued passive investment by Brii Biosciences Limited in AN2 Therapeutics, Inc., which may signal confidence in the company's long-term prospects from a significant institutional investor.
Negatives
- The document does not contain any explicitly negative information regarding AN2 Therapeutics, Inc.'s financial performance or operational outlook.
Risks
- This beneficial ownership filing does not contain information on specific risks related to AN2 Therapeutics, Inc.'s operations, financial health, or strategic direction.
Future Outlook
This beneficial ownership filing does not contain any forward-looking statements or guidance regarding AN2 Therapeutics, Inc.'s future performance or strategic plans.
Management Comments
- Ankang Li, Executive Director, Chief Strategy and Financial Officer of Brii Biosciences Limited, certified the information set forth in the statement.
Industry Context
This document is a beneficial ownership filing and does not provide specific industry context or analysis of broader industry trends. It primarily discloses an institutional investor's stake in a publicly traded company.
Comparison to Industry Standards
- Not applicable as this document is a beneficial ownership filing and does not contain industry-specific financial or operational data for comparison.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can be a factor in investor confidence.
- Management: Awareness of a notable shareholder's position.
Next Steps
- No specific future actions, events, or milestones for AN2 Therapeutics, Inc. are mentioned in this beneficial ownership filing.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of the quarterly period for AN2 Therapeutics, Inc.'s Form 10-Q, which reported shares outstanding. |
| 2024-11-06 | Date as of which 29,878,890 shares of AN2 Therapeutics, Inc. common stock were reported outstanding. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date of filing of the Schedule 13G Amendment No. 1 by Brii Biosciences Limited. |
Keywords
AN2 Therapeutics, Brii Biosciences, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.